Physician profile
Agara Reddy
NPI 1588752364
$11,874.16
in general payments reported to CMS, 2019-2025
35 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,258 · 2020: $1,659 · 2021: $1,589 · 2022: $929 · 2023: $2,194 · 2024: $1,597 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,307 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,307.20 |
| Education | $132.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,698.40 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $1,209.33 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,191.55 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $789.80 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $697.31 | 2019-2025 | Trintellix |
| Validus Pharmaceuticals LLC | $605.21 | 2019-2025 | Equetro |
| Sunovion Pharmaceuticals INC. | $592.45 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $565.88 | 2020-2025 | Fanapt |
| Axsome Therapeutics, INC. | $562.81 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $525.41 | 2020-2025 | Caplyta |
| Abbvie INC. | $508.29 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $417.37 | 2019-2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $375.66 | 2019-2024 | Ingrezza |
| Corium, LLC | $252.57 | 2022-2023 | Azstarys |
| Allergan, INC. | $252.22 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $228.42 | 2023-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $162.81 | 2022-2024 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $154.78 | 2024-2025 | Cobenfy |
| Orexo US, INC. | $150.85 | 2019 | |
| Collegium Pharmaceutical, INC. | $146.59 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $123.20 | 2020-2022 | |
| Shire North American Group INC | $122.15 | 2019 | |
| Eisai INC. | $109.84 | 2020-2021 | |
| Indivior INC. | $100.19 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $74.83 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $69.22 | 2019-2020 | |
| Boston Scientific Corporation | $31.69 | 2025 | Spyglass Discover |
| Jazz Pharmaceuticals INC. | $30.66 | 2021 | |
| Merck Sharp & Dohme LLC | $27.05 | 2021-2023 | Belsomra |
| Neurelis, INC. | $18.90 | 2023 | Valtoco |
| Abbott Laboratories | $18.79 | 2024 | Proclaim |
| Pharmacyclics LLC, An Abbvie Company | $17.70 | 2022 | |
| Sage Therapeutics, LLC | $16.78 | 2024 | |
| Janssen Biotech, INC. | $13.72 | 2023 | |
| Neos Therapeutics, Lp | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agara Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.